FDA Approves First Drug for Neoadjuvant Breast Cancer UseFDA Approves First Drug for Neoadjuvant Breast Cancer Use

Pertuzumab, previously approved for patients with metastatic HER2-positive breast cancer, is now for patients with locally advanced, inflammatory, or early-stage breast cancer who are at high risk. FDA Approvals
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news